A 66-year-old man with prostate cancer presented with intractable pain associated with multifocal bone metastases.
After receiving 180 µCi (1.35 µCi/kg) of 223Ra chloride, radiation survey measured 0.2 mR/h at 1 m, and the patient was discharged to home. He will return monthly for the next 5 months for repeat 223Ra chloride administrations. 223Ra chloride is the first Food and Drug Administration-approved unsealed α-emitting radiopharmaceutical.
Written by:
Colletti PM. Are you the author?
University of Southern California, Los Angeles, CA.
Reference: Clin Nucl Med. 2013 Sep;38(9):724-5.
doi: 10.1097/RLU.0b013e3182a2dd53
PubMed Abstract
PMID: 23867617
UroToday.com Bone Metastases Section
